Retatrutide, a experimental dual stimulator of the GLP-1 target and glucose-dependent released polypeptide (GIP) binding site , is demonstrating promising data in preliminary clinical studies. Current inquiry suggests that retatrutide may offer considerable improvements for patients with type , particularly regarding body mass decrease and glycemic